Skip to main content
SpringerLink
Log in

The neurobiology of social phobia: From pharmacotherapy to brain imaging

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Social phobia is a common psychiatric disorder that is often associated with significant psychiatric comorbidity and disability. There is currently considerable evidence for the efficacy of pharmacotherapy, especially the selective serotonin reuptake inhibitors, in the treatment of this disorder. In addition, researchers have recently begun to explore the underlying neurobiology of social phobia with results that will likely have important implications for future treatments. This article provides a review of the results to date of controlled medication trials. A review of chemical and neuroendocrine challenges, neurotransmitter functioning, and neuroimaging studies in social phobia is provided, followed by a discussion of the implications of these findings for future treatment and research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington DC: American Psychiatric Press; 1994.

    Google Scholar 

  2. Kessler RC, McGonagle KA, Zhao S: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8–19.

    PubMed  CAS  Google Scholar 

  3. Schneier FR, Johnson J, Hornig CD: Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992, 49:282–288.

    PubMed  CAS  Google Scholar 

  4. Liebowitz MR, Gorman JM, Fyer AJ: Social phobia: review of a neglected anxiety disorder. Arch Gen Psychiatry 1985, 42:729–736.

    PubMed  CAS  Google Scholar 

  5. Van Ameringen M, Mancini C, Wilson C, et al.: The prevalence of school dropouts in an anxiety disorders clinic. Presented at 148th Annual Meeting of the American Psychiatric Association. Miami, FL: May 24, 1995.

  6. Heimberg RG, Juster HR: Cognitive behavioural treatments: literature review. InSocial Phobia: Diagnosis Assessment and Treatment. Edited byHeimbergRG, LiebowitzMR, HopeDA, SchneierFR.New York: Guilford Press; 1995:261–309.

    Google Scholar 

  7. TaylorS: Meta-analysis of cognitive-behavioural treatments for social phobia. J Behav Ther Exp Psychiatr 1996, 27:1–9.

    Article  CAS  Google Scholar 

  8. Gelernter CS, Uhde TW, Cimbolic P, et al.: Cognitive-behavioral and. pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991, 48:938–945.

    PubMed  CAS  Google Scholar 

  9. Liebowitz MR, Schneier P, Campeas R, et al.: Phenelzine vs atenolol in social phobia: a placebo controlled trial. Arch Gen Psychiatry 1992, 49:290–300.

    PubMed  CAS  Google Scholar 

  10. Heimberg RG, Liebowitz MR, Hope DA, et al.: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch gen Psychiatry 1998, 55:1133–1141.

    Article  PubMed  CAS  Google Scholar 

  11. Versiani M, Nardi AE, Mundion FD, et al.: Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992, 61:353–360.

    Google Scholar 

  12. Schneier FR, Goetz D, Campeas BF, et al.: Placebo controlled trial of moclobemide in social phobia. Br J Psychiatry 1998, 172:70–77.

    PubMed  CAS  Google Scholar 

  13. Noyes R, Moroz G, Davidson JR, et al.: Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997, 17:247–254.

    Article  PubMed  CAS  Google Scholar 

  14. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia: Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997, 247:71–80.

    Article  Google Scholar 

  15. SteinMB: Medication treatments for panic disorder and social phobia. Depress Anxiety 1998, 7:134–138.

    Article  PubMed  CAS  Google Scholar 

  16. Davidson JRT, Potts NS, Richichi E, et al.: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993, 13:423–428.

    Article  PubMed  CAS  Google Scholar 

  17. van VlietLM, Den BoerJ, Westenberg HGM: Psychopharmacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamine. Psychopharmacology 1994, 115:128–134.

    Article  PubMed  Google Scholar 

  18. Stein MB, Fyer AJ, Davidson JRT, et al.: Fluvoxamine in the treatment of social phobia: a double-blind, placebocontrolled study. Am J Psychiatry 1999, 156:756–760.

    PubMed  CAS  Google Scholar 

  19. Katzelnick DJ, Kobak KA, Greist JH, et al.: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995, 152:1368–1371.

    PubMed  CAS  Google Scholar 

  20. Van Ameringen M, Swinson R, Walker JR, Lane RM: A placebocontrolled study of sertraline in generalized social phobia. Presented at the 19th National Conference of the Anxiety Disorders Association of America. San Diego, CA: March 25–28, 1999.

  21. Blomhoff S, Haug TT, Humble M, et al.:Treatment of generalized social phobia. Presented at the 152nd Annual Meeting of the American Psychiatric Association. Washington, DC: May 20, 1999.

  22. Stein M, Liebowitz M, Lydiard B, et al.: Paroxetine in the treatment of generalized social phobia (social anxiety disorder). JAMA 1998, 280:708–713.

    Article  PubMed  CAS  Google Scholar 

  23. Baldwin D, Bobes J, Stein DJ, et al.: Paroxetine in social phobia/ social anxiety disorder. Br J Psychiatry 1999, 175:120–126.

    PubMed  CAS  Google Scholar 

  24. DavidsonJRT: Pharmacotherapy of social anxiety disorder. J Clin Psychiatry 1998, 59:47–51.

    CAS  Google Scholar 

  25. Baldwin DS, and the SmithKline Beecham Social Anxiety Disorder Study Group: Paroxetine in the treatment of social anxiety disorder (social phobia): an overview. Presented at 11th Congress of the European College of Neuropsychopharmacology (ECNP). Paris, France: October 31–November 4, 1998.

  26. AllgulanderC: Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1998, 100:193–198.

    Google Scholar 

  27. Clarke DB, Agras WS: The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991, 148:598–605.

    Google Scholar 

  28. van VlietLM, den Boer JA, Westenberg HGM, et al.: Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997, 58:164–168.

    PubMed  Google Scholar 

  29. Emmanuel NP, Johnson M, Villareal G: Imipramine in the treatment of social phobia: a double blind study. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology. Kamuela, Hawaii: December 8–12, 1997.

  30. Falloon IR, Lloyd GG, Harpin R: The treatment of social phobia: real-life rehearsal with non-professional therapists. J Nerv Ment Dis 1981, 169:180–184.

    Article  PubMed  CAS  Google Scholar 

  31. Turner SM, Beidel DC, Jacob RG: Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994, 62:350–358.

    Article  PubMed  CAS  Google Scholar 

  32. Bell J, DeVeaugh-Geiss J:Multicenter trial of a 5-HT3 antagonist, ondansetron, in social phobia. Presented at the 33rd Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico: December 12–16, 1994.

  33. Pande AC, Davidson JR, Jefferson JW, et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999, 19:341–348.

    Article  PubMed  CAS  Google Scholar 

  34. Feltner DE, Pollack MH, Davidson JRT, et al.: A placebocontrolled study of pregabalin in the treatment of social phobia. Poster presented at Anxiety Disorders Of America’s 20th Annual Conference. Washington, DC: March 23–26, 2000.

  35. Van AmeringenM, Mancini C, Oakman J: Nefazodone in the treatment of social phobia. J Clin Psychiatry 1999, 60:96–100.

    Article  PubMed  Google Scholar 

  36. Worthington III JJ, Zucker BG, Calvin SL, et al.: Nefazodone for social phobia: a clinical case series. Depress Anxiety 1998, 8:131–133.

    Article  PubMed  Google Scholar 

  37. Kelsey JE, Selvig AL, Knight BT, et al.: Treatment of generalized social phobia with the 5HT2 antagonist nefazodone. Poster presented at Anxiety Disorders Of America’s 20th Annual Conference. Washington, DC: March 23–26, 2000.

  38. Emmanuel NP, Czepowicz VC, Ware MR, et al.:Venlafaxine in social phobia: a case series [abstract]. Presented at the 148th Annual Meeting of the American Psychiatric Association. Miami, FL: May 24, 1995. Abstract NR373:156.

  39. KelseyJE: Venlafaxine in social phobia. Psychopharmacol Bull 1995, 31:767–771.

    PubMed  CAS  Google Scholar 

  40. van Vliet IM, Westenberg HGM, van Megen HJGM: Clinical effects of venlafaxine in social phobia. Presented at the 11th Congress of the European College of Neuropsychopharmacology (ECNP). Paris. France: October 31–November 4, 1998.

  41. Altamura AC, Pioli R, Vitto M, Mannu P: Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999, 14:239–245.

    Article  PubMed  CAS  Google Scholar 

  42. Emmanuel NP, Lydiard RB, Ballenger JC: Treatment of social phobia with bupropion [letter]. J Clin Psychopharmacol 1991, 11:276–277.

    Article  PubMed  CAS  Google Scholar 

  43. GoldsteinS: Treatment of social phobia with clonidine. Biol Psychiatry 1987, 22:369–372.

    Article  PubMed  CAS  Google Scholar 

  44. KoobGF: Corticotropin-releasing factor, norepinephrine, and stress. Biological Psychiatry 1999, 46:1167–1180.

    Article  PubMed  CAS  Google Scholar 

  45. SariaA: The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacology 1999, 375:51–60.

    Article  CAS  Google Scholar 

  46. StahlSM: Peptides and psychiatry part 3: substance P and serendipity: novel psychotropics are a possibility. J Clin Psychiatry 1999, 60:140–141.

    PubMed  CAS  Google Scholar 

  47. Liebowitz MR, Fyer AJ, Gorman JM, et al.: Specificity of lactate infusions in social phobia versus panic disorders. Am J Psychiatry 1985, 142:947–950.

    PubMed  CAS  Google Scholar 

  48. Tancer ME, Stein MB, Uhde TW: Lactate response to caffeine in panic disorder; a replication using an "anxious control group". Biol Psychiatry 1991, 29:57.

    Google Scholar 

  49. Gorman JM, Papp LA, Martinez J, et al.: High-dose carbon dioxide challenge test in anxiety disorder patients. Biol Psychiatry 1990, 28:743–757.

    Article  PubMed  CAS  Google Scholar 

  50. Papp LA, Klein DF, Martinez J, et al.: Diagnostic and substance specificity of carbon dioxide induced panic. Am J Psychiatry 1993, 150:250–257.

    PubMed  CAS  Google Scholar 

  51. Caldirola D, Perna G, Arancio C, Bertani A, Bellodi L: The 35% carbon dioxide challenge test in patients with social phobia. Psychiatry Res 1997, 71:41–48.

    Article  PubMed  CAS  Google Scholar 

  52. UhdeT: Anxiety and growth disturbance; is there a connection? A review of biological studies in social phobia. J Clin Psychol 1994, 55(Suppl 6):17–27.

    Google Scholar 

  53. Bradwejn J: CCK. Presentation at British Association of Psychopharmacology summer meeting. Cambridge England: July 13–17, 1997.

  54. Coupland NJ, Bell C, Potokar JP, et al.: Flumazenil Challenge in Social Phobia. Depress Anxiety 2000, 11:27–30

    Article  PubMed  CAS  Google Scholar 

  55. Uhde TW, Taner ME, Gelernter CS, et al.: Normal urinary free cortisol and postdexamethasone cortisol in social phobia. J Affective Disord 2000, in press.

  56. Potts NLS, Davidson JRT, Krishnan KRR, et al.: Levels of urinary free cortisol in social phobia. J Clin Psychiatry 1991, 52(Suppl 11):41–42.

    PubMed  Google Scholar 

  57. Tancer ME, Stein MB, Bessette BB, et al.: The hypothalmicpituitary-thyroid axis in social phobia. Am J Psychiatry 1990, 147:929–933.

    PubMed  CAS  Google Scholar 

  58. Tancer ME, Stein MB, Uhde TW: Effects of TRH on blood pressure and heart rate in social phobia patients, panic disorder patients and normal controls; results of a pilot study. Biol Psychiatry 1990, 27:781–783.

    Article  PubMed  CAS  Google Scholar 

  59. Van AmeringenM, Mancini C, Farvolden P, Oakman J: Pharmacotherapy for Social Phobia: What Works, What Might Work, and What Does Not Work at All. CNS Spectrums 1999, 4:61–68. A recent and comprehensive review of evidence for various pharmacotherapies in the treatment of social phobia.

    PubMed  Google Scholar 

  60. Higley JD, King ST Jr, Hasert MF, et al.: Stability of interindividual differences in serotonin function and its relationship to severe aggression and competent social behavior in rhesus macaque females. Neuropsychopharmacology 1996, 14:67–76.

    Article  PubMed  CAS  Google Scholar 

  61. Raleigh MJ, Brammer GL, Yuwiler A, et al.: Serotonergic influences on the social behavior of vervet monkeys (Cercopithecus aethiops sabaeus). Exp Neurol 1980, 68:322–334.

    Article  PubMed  CAS  Google Scholar 

  62. Raleigh MJ, Brammer GL, McGuire MT, Yuwiler A: Dominant social status facilitates the behavioral effects of serotonergic agonists. Brain Res 1985, 348:274–282.

    Article  PubMed  CAS  Google Scholar 

  63. Westergaard GC, Mehlman PT, Suomi SJ, Higley JD: CSF 5-HIAA and aggression in female macaque monkeys: species and interindividual differences. Psychopharmacology 1995, 146:440–446.

    Article  Google Scholar 

  64. Knutson B, Wolkowitz OM, Cole SW, et al.: Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998, 155:373–379. A very interesting article describing the effects of paroxetine vs placebo on psychiatrically healthy volunteers. SSRI administration led to a decrease in negative affect but did not alter positive affect as well as increases on a behavioral index of affiliation, with affiliation correlating r = 0.65 with plasma paroxetine levels.

    PubMed  CAS  Google Scholar 

  65. Stein MB, Delaney SM, Chartiet M, et al.: 3H paroxetine binding to platelets of patients with social phobia; comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry 1995, 37:224–228.

    Article  PubMed  CAS  Google Scholar 

  66. Tancer ME, Mailman RB, Stein MB, et al.: Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety 1994/1995, 1:216–223.

    Google Scholar 

  67. Mikkelson EJ, Deltor J, Cohen DJ: School avoidance and social phobia triggered by haloperdidol in patients with Tourette’s syndrome. Am J Psychiatry 1981, 138:1572–1576.

    Google Scholar 

  68. Richard IH, Schiffer RB, Kurlan R: Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996, 8:383–392.

    PubMed  CAS  Google Scholar 

  69. King R, Mefford I, Wang C, et al.: CSF dopamine levels correlate with extraversion in depressed patients. Psychiatry Res 1986, 19:305–310.

    Article  PubMed  CAS  Google Scholar 

  70. Johnson M, Lydiard R, Zealberg J, et al.: Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biol Psychiatry 1994, 36:425–427.

    Article  PubMed  CAS  Google Scholar 

  71. Levin AP, Saoud J, Struaman T, et al.: Responses of generalized and discrete social phobics during public speaking. J Affect Disord 1993, 7:207–221.

    Google Scholar 

  72. Stein MB, Tancer ME, Uhde TW: Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders: comparison of patients with panic disorder and social phobia and normal control subjects. Arch Gen Psychiatry 1992, 49:311–317.

    PubMed  CAS  Google Scholar 

  73. Stein MB, Asmundson G, Chartier M: Autonomic responsivity in generalized social phobia. J Affective Disorders 1994, 31:211–221.

    Article  CAS  Google Scholar 

  74. Coupland NJ, Bailey JE, Potakar JP, et al.: Abnormal cardiovascular responses to standing in panic disorder and social phobia. British Association of Psychopharmacology summer meeting. J Psychopharmacology 1991, 9(Suppl A19):73.

    Google Scholar 

  75. Tancer ME, Stein MB, Uhde TW: Growth hormone response to IV clonidine in social phobia; comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry 1994, 34:252–256.

    Google Scholar 

  76. Potts NL, Davidson JR, Krishnan KR, Doraiswamy PM: Magnetic resonance imaging in social phobia. Psychiatry Res 1994, 52:35–42.

    Article  PubMed  CAS  Google Scholar 

  77. Davidson JRT, Krishnan KRR, Charles HC, et al.: Magnetic resonance spectroscopy in social phobia: preliminary findings. J Clin Psychiatry 1993, 54(Suppl 12):19–25.

    PubMed  Google Scholar 

  78. Tupler LA, Davidson JRT, Smith RD, et al.: A repeat proton magnetic resonance spectroscopy study in social phobia. Biol Psychiatry 1997, 42:419–424.

    Article  PubMed  CAS  Google Scholar 

  79. Stein MB, Leslie WD: A brain single photon-emission computed tomography (SPECT) study of generalized social phobia. Biol Psychiatry 1996, 39:825–828.

    Article  PubMed  CAS  Google Scholar 

  80. Tiihonen J, Kuikka J, Bergstrom K, et al.: Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997, 154:239–242.

    PubMed  CAS  Google Scholar 

  81. Li Dm, Chokka P, McEwan AJB, et al.: The relationship of striatal dopamine with social phobia and gender: a SPECT study. Poster presented at the Biological Psychiatry Meeting. Washington, DC: May 13–15, 1999,

  82. Schneier FR, Liebowitz MR, Abi-Dargham A, et al.: Low dopamine D2 receptor binding potential in social phobia. Am J Psychiatry 2000, 157:457–459. This study compared D2 receptor binding potential in patients with social phobia and control subjects. Mean D2 receptor binding potential was significantly lower in the subjects with social phobia as compared with controls.

    Article  PubMed  CAS  Google Scholar 

  83. Birbaumer N, Grodd W, Diedrich O, et al.: MRI reveals amygdala activation to human faces in social phobics. Neuroreport 1998, 9:1223–1226.

    Article  PubMed  CAS  Google Scholar 

  84. Malizia AL, Wilson SJ, Bell CM, et al.: Neural correlates of anxiety provocation in social phobia. Neuroimage 1997, 5:S301.

    Google Scholar 

  85. AsendorpfJB: Shyness as a final common pathway for two different kinds of inhibition. J Pers Soc Psychol 1989, 57:481–492.

    Article  Google Scholar 

  86. AsendorpfJB: Development of inhibition during childhood: Evidence for situational specificity and a two-factor model. Dev Psychol 1990, 26:721–730.

    Article  Google Scholar 

  87. AsendorpfJB: Abnormal shyness in children. J Child Psychol Psychiatry 1993, 34:1069–1081.

    Article  PubMed  CAS  Google Scholar 

  88. BussAH: Two kinds of shyness. InSelf-Related Cognitions in Anxiety and Motivation. Edited bySchwarzerR. Hillsdale, NJ: Lawrence Erlbaum Associates; 1995.

    Google Scholar 

  89. BussAH,PlominR: Temperament: Early Developing Personality Traits. Hillsdale, NJ: Lawrence Erlbaum Associates; 1984.

    Google Scholar 

  90. LeDouxJ: The Emotional Brain. New York: Simon & Schuster; 1996.

    Google Scholar 

  91. KaganJ: The concept of behavioral inhibition to the familiar. In Perspectives on Behavioral Inhibition. Edited byReznickJS. Chicago: University of Chicago Press; 1989.

    Google Scholar 

  92. Grant KA, Shively CA, Nader MA, et al.: Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. Synapse 1998, 29:80–83. This article presents evidence that social status in cynomolgus monkeys is associated with striatal D2 receptor binding.

    Article  PubMed  CAS  Google Scholar 

  93. Cohen JD, Braver TS, O’Reilly RC: A computational approach to prefrontal cortex, cognitive control and schizophrenia: recent developments and current challenges. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 1996, 351:1515–1527.

    Article  PubMed  CAS  Google Scholar 

  94. Depue RA, Luciana M, Arbisi P, et al.: Dopamine and the structure of personality: relation of agonist-induced dopamine activity to positive emotionality. J Pers Soc Psychology 1994, 67:485–498.

    Article  CAS  Google Scholar 

  95. Egelman DM, Person C, Montague PR: A computational role for dopamine delivery in human decision-making. J Cognitive Neurosci 1998, 10:623–630.

    Article  CAS  Google Scholar 

  96. Contreras-Vidal JL, Schultz W: A predictive reinforcement model of dopamine neurons for learning approach behavior. J Comput Neurosci 1999, 6:191–214.

    Article  PubMed  CAS  Google Scholar 

  97. KoobGF: Hedonic valence, dopamine and motivation. Mol Psychiatry 1996, 1:186–189.

    PubMed  CAS  Google Scholar 

  98. SchultzW: Predictive reward signal of dopamine neurons. Jo Neurophysiol 1998, 80:1–27.

    CAS  Google Scholar 

  99. GrayJA: The Neuropsychology of Anxiety. Oxford:Oxford University Press; 1982.

    Google Scholar 

  100. Deakin JFW, Graeff FG: 5-HT and mechanisms of defense. J Psychopharmacol 1991, 5:305–315.

    Article  Google Scholar 

  101. Hansenne M, Ansseau M: Harm avoidance and serotonin. Biological Psychiatry 1999, 51:77–81.

    Article  CAS  Google Scholar 

  102. DubovskySL: Beyond the serotonin reuptake inhibitors: Rationales for the development of new serotonergic agents. J Clin Psychiatry 1994, 55(Suppl 2):34–44.

    PubMed  Google Scholar 

  103. Chavira DA, Stein MB: The shyness spectrum. CNS Spectrums 1999, 4:11:20–26. A review of similarities and differences between shyness and social phobia, including a discussion of a potential precursor to social phobia: childhood behavioral inhibition.

    Google Scholar 

  104. Oakman J, Van AmeringenM, Mancini C, Farvolden P: in the treatment of social phobia. In Shyness. Edited byCrozierWR.Cambridge: Routledge Press; 2000, in press

    Google Scholar 

  105. Fahlen T, Nilsson HL, Borg K, et al.: Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand 1995, 92:351–358.

    PubMed  CAS  Google Scholar 

  106. van VlietIM, den Boer JA, Westenberg HGM: Psychopharmacological treatment of social phobia: clinical and biochemical effects if brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992, 2:21–29.

    Article  PubMed  Google Scholar 

  107. Lott M, Greist JH, Jefferson JW, et al.: Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997, 17:255–260.

    Article  PubMed  CAS  Google Scholar 

  108. Baldwin D, Bobes J, Stein DJ, et al.: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Br J Psychiatry 1999, 175:120–126.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anxiety Disorders Clinic, McMaster University Medical Centre, Hamilton Health Sciences Corporation, 1200 Main Street West, L8N 3Z5, Hamilton, ON, Canada

    Michael Van Ameringen MD, Catherine Mancini MD & Peter Farvolden PhD

  2. University of Waterloo, Waterloo, ON, Canada

    Jonathan Oakman PhD

Authors
  1. Michael Van Ameringen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine Mancini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Farvolden PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan Oakman PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Ameringen, M., Mancini, C., Farvolden, P. et al. The neurobiology of social phobia: From pharmacotherapy to brain imaging. Curr Psychiatry Rep 2, 358–366 (2000). https://doi.org/10.1007/s11920-000-0082-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-000-0082-7

Keywords

Search

Navigation